Incidence of and risk factors for HIV-associated distal sensory polyneuropathy
- 25 June 2002
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 58 (12), 1764-1768
- https://doi.org/10.1212/wnl.58.12.1764
Abstract
Objective: To assess the incidence of and risk factors for distal sensory polyneuropathy (DSP) in a cohort of HIV-infected subjects. Methods: We followed 272 subjects semiannually for up to 30 months. DSP was diagnosed if subjects had decreased or absent ankle jerks, decreased or absent vibratory perception at the toes, or decreased pinprick or temperature in a stocking distribution. Subjects were further classified at each visit as having asymptomatic DSP (ADSP) (signs only) or symptomatic DSP (SDSP) if, in addition to the neurologic signs, paresthesias or pain was reported. Results: At baseline, 45% of the subjects did not meet criteria for DSP, 20% met criteria for ADSP, and 35% met criteria for SDSP. Dideoxynucleoside therapy was used by 23% of the patients, and this treatment was independent of their neuropathy status. In longitudinal univariate analyses, history of AIDS diagnoses (hazard ratio [HR] = 1.89; p = 0.02) and lower CD4 cell count (HR = 0.69; p = 0.0006) were risk factors for incident DSP (ADSP or SDSP). However, for incident SDSP only, in addition to history of AIDS diagnoses, mood and neurologic (other than DSP) and functional abnormalities were significant risk factors. Functional abnormalities remained a significant risk factor in a multiple regression analysis. The presence of ADSP and the use of dideoxynucleosides at baseline were not significant risk factors for incident SDSP. The Kaplan–Meier estimate of the 1-year incidence of SDSP was 36%. Conclusion: Subjects with moderate-to-severe immunosuppression from HIV infection commonly have SDSP. However, sex, use of dideoxynucleosides, and presence of ADSP were not significant risk factors for SDSP.Keywords
This publication has 18 references indexed in Scilit:
- 126th Annual Meeting, American Neurological Association: Abstracts: Plenary Session: NeurovirologyAnnals of Neurology, 2001
- A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infectionNeurology, 2000
- Clinical confirmation of the American Academy of Neurology algorithm for HIV-1-associated cognitive/motor disorderNeurology, 1996
- Low-dose zalcitabine-related toxic neuropathyNeurology, 1996
- Epidemiology of AIDS Dementia Complex in EuropeJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Teaching tape for the motor section of the unified Parkinson's disease rating scaleMovement Disorders, 1995
- Temporal trends in the incidence of HTV‐1‐related neurologic diseasesNeurology, 1994
- 2',3'‐Dideoxycytidine (ddC) toxic neuropathyNeurology, 1993
- The CES-D ScaleApplied Psychological Measurement, 1977
- The use of the nitrogen mustards in the palliative treatment of carcinoma.With particular reference to bronchogenic carcinomaCancer, 1948